Longeveron Rallies 20% In Morning Trade

On:

Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.

Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).

The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.

LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.

Source: Read Full Article

Lates News:
  1. VIZIO Climbs 4% On Reporting 100% Growth In Direct Advt. Commitments
  2. Greenpeace Says Bitcoin Is ‘Defiantly Refusing To Accept Its Climate Responsibility’
  3. RXO Adds 8% In Morning Trade As Earnings Beat The Street View
  4. Bitcoin Falls to Lowest Level in 3 Months As Market Awaits Outcome of FOMC Meeting
  5. Why Wall Street Sees Bitcoin Falling Sharply To $10,000